Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 3/20 | 0.50 |
| ▸ | AURKA | O14965 | 8/20 | 0.48 |
| ▸ | EGFR | P00533 | 5/20 | 0.47 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.45 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | UBE2N | P61088 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | MERTK | Q12866 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | RAD52 | P43351 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4531353 | 0.94 | AURKA (0.45) | CHEK1AURKAEGFRTNK2KDM4E | |
| SCHEMBL6750702 | 0.94 | KDM4E (0.54) | CHEK1AURKAEGFRTNK2KDM4E | |
| SCHEMBL6750708 | 0.94 | KDM4E (0.54) | CHEK1AURKAEGFRTNK2KDM4E | |
| SCHEMBL4530234 | 0.94 | KDM4E (0.54) | CHEK1AURKAEGFRTNK2KDM4E | |
| SCHEMBL4519959 | 0.93 | KDM4E (0.53) | CHEK1AURKAEGFRTNK2KDM4E | |
| SCHEMBL4519965 | 0.93 | KDM4E (0.53) | CHEK1AURKAEGFRTNK2KDM4E | |
| SCHEMBL14923138 | 0.92 | AURKA (0.44) | CHEK1AURKAEGFRKDM4EALDH1A1 | |
| SCHEMBL2178672 | 0.89 | EGFR (0.44) | CHEK1AURKAEGFRTNK2MAP2K1 | |
| Monoethanolamine SCHEMBL4531691 | 0.89 | KDM4E (0.52) | CHEK1AURKAEGFRTNK2KDM4E | |
| SCHEMBL2180137 | 0.88 | AURKA (0.40) | CHEK1AURKAEGFRMAP2K1MERTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110166163-A1 | SUBSTITUTED FUROPYRIMIDINES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166163-A1 | SUBSTITUTED FUROPYRIMIDINES AND USE THEREOF | DPYD, TPMT, TYMP | CHEK1 800/4885AURKA 2987/4885EGFR 4267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.